April 17, 2026

FURL vs Mini-PCNL in 2 to 3 cm Stones

Review reports comparable stone-free rates with suction-assisted ureteroscopy

Conexiant

April 17, 2026

Incretin Trials Often Exceed Muscle-Loss Benchmarks

Systematic review finds muscle-related losses frequently surpass expected thresholds during weight loss, though clinical impact remains unclear

Conexiant

April 17, 2026

Retinal Imaging Model Aids CAD Detection

Fundus-based model showed moderate-to-good accuracy and improved performance when combined with clinical risk factors in a high-risk cohort

Conexiant

April 16, 2026

GLP-1 Drugs Linked to GI Effects, Uncertain Signals

Umbrella review evaluates over 1,700 trials to assess noncardiometabolic outcomes beyond weight and glycemic effects.

Conexiant

April 16, 2026

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Conexiant

April 15, 2026

ApoB Goal Cost-Effective in Primary Prevention

Strategy increased quality-adjusted life-years and showed favorable cost-effectiveness vs low-density lipoprotein cholesterol and non–high-density lipoprotein cholesterol goals

Conexiant

April 15, 2026

Diabetes Self-Care Declines During Breast Cancer Treatment

Patients experience reduced monitoring, emotional distress, and gaps in coordinated care during adjuvant therapy

Conexiant

April 15, 2026

Diabetic Retinal Disease Rates Narrow by Diabetes Type

US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.

Conexiant

April 13, 2026

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

Conexiant

April 10, 2026

Influenza Vaccine Dose and Dementia Outcomes

US claims data compare high- vs standard-dose formulations in patients aged 65 years or more over 3 years of follow-up

Conexiant